A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
        Principal Investigator
        
            
                Melody Cobleigh, MD
                
        
        
        
                Status
        Terminated
        
        	
        	
        		Date Opened To Accrual
        		November 10 2008
        	 
        	
        	
        	
        	
        		Date Closed to Accrual
        		December 08 2014
        	 
        	
        	
        	
        		Date of Study Termination
        		June 02 2025
        	 
        	
         
        Disease Site
        Breast [BR]
        Breast
        Phase
        III
        Developmental Therapeutics
        No
        Primary Objective
        To determine the value of trastuzumab given during radiation therapy (RT) compared to RT alone in preventing the subsequent occurrence of ipsilateral breast cancer recurrence, ipsilateral skin cancer recurrence, or ipsilateral DCIS
(IIBCR-SCR-DCIS) in women with HER2-positive DCIS resected by lumpectomy.
        Patient Population
        Women with HER2-positive ductal carcinoma in situ (DCIS) resected by lumpectomy
        Target Accrual
        2000
     
    
   
        
        
         Patient Study Webpage
        
            There is no available patient study webpage available for this trial at this time.